Esperion is a commercial-stage biopharmaceutical company bringing innovative cardiometabolic and rare/orphan disease therapies to market for patients with unmet medical needs. Founded in 2008 and headquartered in Michigan, Esperion built its business on Nexletol® (bempedoic acid) and Nexlizet® (bempedoic acid and ezetimibe), once-daily oral tablets that reduce Low-Density Lipoprotein (LDL, or bad cholesterol) in adults with high blood cholesterol, most specifically those who are statin-intolerant. In 2026, Esperion expanded its portfolio with the acquisition of Enbumyst™ (bumetanide nasal spray), the first and only FDA-approved nasal spray for edema associated with congestive heart failure, hepatic disease, and renal disease. Esperion serves cardiologists and primary care physicians addressing cardiovascular disease and associated conditions across the US and international markets.